ReviewMolecular microbiology2021
The Escherichia coli FadR transcription factor: Too much of a good thing?
Review in Molecular microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Genome-wide identification of conditionally essential genes for growth in the presence of sulfamethoxazole and trimethoprim in sulfamethoxazole- and trimethoprim-resistantMicrobiology spectrum · 2026Article
- Long-chain fatty acid homeostasis contributes to survival of uropathogenicJournal of bacteriology · 2026Article
- Aerobicity stimulon iniScience · 2026Article
- The GntR/VanR transcription regulator AlkR represses AlkB2 monooxygenase expression and regulatesmLife · 2025Article
- In silico analysis of non-conventional gene targets for genetic interventions to enhance fatty acid production: a review.Molecular biology reports · 2025Review
- Diversification of single-cell growth dynamics under starvation influences subsequent reproduction in a clonal bacterial population.The ISME journal · 2025Article
- Bacterial acquisition of host fatty acids has far-reaching implications on virulence.Microbiology and molecular biology reviews : MMBR · 2024Review
- Enhanced biosynthesis of poly(3-hydroxybutyrate) in engineered strains of Pseudomonas putida via increased malonyl-CoA availability.Microbial biotechnology · 2024Article
- Regulation of fadR on the ROS defense mechanism in Shewanalla oneidensis.Biotechnology letters · 2024Article
- Genetic evidence for functional diversification of gram-negative intermembrane phospholipid transporters.PLoS genetics · 2024Article
- Genetic evidence for functional diversification of gram-negative intermembrane phospholipid transporters.bioRxiv : the preprint server for biology · 2024Article
- Transcriptional and Metabolic Response of a Strain ofBiotech (Basel (Switzerland)) · 2024Article
- Unsaturated fatty acid synthesis in bacteria: Mechanisms and regulation of canonical and remarkably noncanonical pathways.Biochimie · 2024Review
- Evidence for endogenous hydrogen peroxide production by E. coli fatty acyl-CoA dehydrogenase.PloS one · 2024Article
- Dual stimulus-responsive renewable nanoadsorbent for selective adsorption of low-density lipoprotein in serum.Regenerative biomaterials · 2024Article
- Medium-Chain-Length Fatty Acid Catabolism in Cupriavidus necator H16: Transcriptome Sequencing Reveals Differences from Long-Chain-Length Fatty Acid β-Oxidation and Involvement of Several Homologous Genes.Applied and environmental microbiology · 2023Article
- Determination of Mutational Timing of Colistin-Resistance Genes throughPharmaceutics · 2023Article
- Emerging mechanisms by which endocannabinoids and their derivatives modulate bacterial populations within the gut microbiome.Advances in drug and alcohol research · 2023Review
- FabT, a Bacterial Transcriptional Repressor That Limits Futile Fatty Acid Biosynthesis.Microbiology and molecular biology reviews : MMBR · 2022Review
- The Classical, Yet Controversial, First Enzyme of Lipid Synthesis: Escherichia coli Acetyl-CoA Carboxylase.Microbiology and molecular biology reviews : MMBR · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Escherichia coli FadR is a transcription factor regulated by acyl-CoA thioester binding that optimizes fatty acid (FA) metabolism in response to environmental FAs. FadR represses the fad genes of FA degradation (β-oxidation) and activates the fab genes of FA synthesis thereby allowing E. coli to have its cake (acyl chains for phospholipid synthesis) and eat it (degrade acyl chains to acetyl-CoA). Acyl-CoA binding of FadR derepresses the transcription of the fad genes and cancels fab gene transcriptional activation. Activation of fab genes was thought restricted to the fabA and fabB genes of unsaturated FA synthesis, but FadR overproduction markedly increases yields of all FA acyl chains. Subsequently, almost all of the remaining fab genes were shown to be transcriptionally activated by FadR binding, but binding was very weak. Why are the low-affinity sites retained? What effects on cell physiology would result from their conversion to high-affinity sites (thereby mimicking FadR overproduction)? Investigations of E. coli cell size determinants showed that FA synthesis primarily determines E. coli cell size. Upon modest induction of FadR, cell size increases, but at the cost of growth rate and accumulation of intracellular membranes. Greater induction resulted in further growth rate decreases and abnormal cells. Hence, too much FadR is bad. FadR is extraordinarily conserved in γ-proteobacteria but has migrated. Mycobacterium tuberculosis encodes FadR orthologs one of which is functional in E. coli. Strikingly, the FadR theme of acyl-CoA-dependent transcriptional regulation is found in a different transcription factor family where two Bacillus species plus bacterial and archaeal thermophiles contain related proteins of similar function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.